医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Acelity Supports Education and Development of Early-Stage Surgeons

2015年06月11日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Acelity, a global wound care and regenerative medicine company, is hosting the Acelity Surgical Wound Forum (ASWF), which starts today in Prague, Czech Republic. ASWF is a three-day educational event for more than 350 early-stage surgeons from around the world including Europe, United Arab Emirates, South Africa and Asia. In addition to a robust scientific program that has been accredited by the Association of Surgeons of Great Britain and Ireland (ASGBI), ASWF will include sessions on economics and healthcare compliance requirements when collaborating with industry, topics not typically covered in medical school, but important for a successful career in today’s healthcare environment.

“There is a huge demand for this kind of collaborative meeting for early-stage surgeons that not only enables scientific learning around procedural pathways, but also provides practical learning and best practice advice from more experienced surgeons and specialists,” said Prof. Jerome Pereira, MD, FRCSEd, FRCS, Consultant Oncoplastic Breast Surgeon and Co-Chair of the ASWF. “I am grateful to Acelity for their support in providing such a comprehensive program that will undoubtedly deliver significant educational value to the attending surgeons at a critical juncture in their career.”

New to the ASWF scientific program this year is a Call for Abstracts reporting on appropriate use of Acelity products and related advanced wound care topics. Forty abstracts were submitted, and the top three abstracts (chosen by an independent, blinded panel), will be announced during the ASWF and delivered as podium presentations, with the authors’ institution receiving an educational scholarship grant.

“At Acelity, we believe in enabling better futures. Investing in the education of surgeons who have just started their careers is an excellent way for us to help equip participating surgeons with practical skills to ultimately enable better futures for the patients they treat,” said Laura Piccinini, President, Developed Markets, Acelity.

ASWF is an annual educational event intended to facilitate peer-to-peer learning, the exchange of innovative concepts in surgery and wound care, and the safe and effective use of new technologies. This year, our world-renowned faculty is led by Prof. Jerome Pereira of James Paget Hospital, Great Yarmouth & University of East Anglia in the UK, and Dr. Ondrej Mestak, MD, PhD, Plastic Surgeon, Esthé Clinica and Department of Plastic Surgery, Bulovka Hospital; Deputy Head for Education, 1st Medical Faculty of Charles University, Prague in the Czech Republic.

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150611005369/en/

CONTACT

Acelity
Corporate Communications:
Sarah Swift, +44 797 0742 696
sswift@acelity.com
or
Investor
Relations:
Caleb Moore, +1-210-255-6433
caleb.moore@acelity.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表